Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
.png)
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test.
Pharmaceutical company PharmaKure has announced a novel whole blood test that can quantify blood-based biomarkers for Alzheimer’s Disease with successful study results. These biomarkers can be identified to provide early warning of cognitive decline in patients with Alzheimer’s Disease.
By testing whole blood samples, the study accessed a number of biomarkers for the stratification of Alzheimer’s subjects previously tested for amyloid deposits. This was done using brain PET imaging or cerebrospinal fluid (CSF). The levels of these biomarker proteins were measured in the blood of these patients at the early stages of the disease. The proteins included amyloid-β, α-synuclein, and Tau, key biomarkers all associated with Alzheimer’s Disease pathology. Machine learning technology was used to combine blood biomarker and patient data to develop predictive tools.
It was demonstrated that whole blood can be used to identify those at high risk of developing Alzheimer’s Disease. The machine learning software also allowed for the identification of which biomarkers are most useful to predict high Alzheimer’s Disease risk. The whole blood test is now PharmaKure’s proprietary ALZmetrixTM blood test.
Professor Andrew Doig, Head of R&D at PharmaKure, comments: “We are particularly pleased to find that our ALZmetrix blood test can differentiate between patient groups that are amyloid positive or amyloid negative with 97% accuracy to predict those at highest risk of Alzheimer’s Disease. Age, APOE4 and pTau are the most useful features in the prediction. We have also shown that blood can track disease progression, primarily using levels of Tau and pTau.”
CEO at PharmaKure Limited Dr Farid Khan adds: “These results represent an important step in developing whole blood tests to address a major unmet need for an alternative to PET and CSF scans. This study has demonstrated how to get early warning signs of cognitive decline using whole blood. We will be using the exciting data to expand our ALZmetrix test to additional patients and new biomarkers.”
Additionally, a key advantage of testing whole blood samples is the ability to develop a screening system to detect Alzheimer’s before major memory problems become apparent. Early treatment is paramount to providing better health outcomes, improving patients’ quality of life, and lowering healthcare and system costs. “Using the ALZmetrix test for Alzheimer’s could provide a low cost, easily accessible test for stratifying patients for clinical studies, as an alternative to expensive brain scans or other plasma-based tests,” Dr Bob Smith, Clinical Director at PharmaKure, states.
Related News
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Trump administration halts global supply of HIV, malaria, tuberculosis drugs
In various memos circulated to the United States Agency for International Development (USAID), the Trump administration has demanded contractors and partners to immediately stop work in supplying lifesaving drugs for HIV, malaria, and tuberculosis to c... -
News 2024 Drug Approvals: a lexicon of notable drugs and clinical trials
50 drugs received FDA approval in 2024. The centre for biologics evaluation and research also identified six new Orphan drug approvals as under Biologics License Applications (BLAs). The following list picks out key approvals from the list, and highlig...
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance